HU227742B1
(en)
|
1996-10-18 |
2012-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
EP1471908B1
(en)
*
|
2002-10-17 |
2007-08-08 |
Teva Pharmaceutical Industries Ltd. |
Process for preparing losartan potassium with improved flowability
|
AU2003278422A1
(en)
*
|
2002-10-31 |
2004-05-25 |
Ranbaxy Laboratories Limited |
Amorphous form of losartan potassium
|
IL154370A0
(en)
*
|
2003-02-10 |
2003-09-17 |
Chemagis Ltd |
Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
|
ITMI20030328A1
(it)
*
|
2003-02-25 |
2004-08-26 |
Dinamite Dipharma S P A In Forma A Bbreviata Diph |
Polimorfi di losartan potassio e procedimento per la loro preparazione.
|
WO2004076443A1
(en)
*
|
2003-02-25 |
2004-09-10 |
Hetero Drugs Limited |
Amorphous form of losartan potassium
|
WO2004076442A1
(en)
*
|
2003-02-28 |
2004-09-10 |
Ranbaxy Laboratories Limited |
Polymorphs of losartan
|
US7345071B2
(en)
|
2003-05-07 |
2008-03-18 |
Ipca Laboratories Limited |
Process for the synthesis of Losartan potassium
|
AR045596A1
(es)
|
2003-09-05 |
2005-11-02 |
Vertex Pharma |
Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
|
ITMI20032472A1
(it)
*
|
2003-12-16 |
2005-06-17 |
Dinamite Dipharma S P A In Forma A Bbreviata Diph |
Procedimento per la preparazione di losartan potassio cristallino
|
WO2005066158A2
(en)
*
|
2004-01-06 |
2005-07-21 |
Ipca Laboratories Limited |
An improved process for the synthesis of losartan potassium
|
US7692023B2
(en)
|
2004-02-11 |
2010-04-06 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
WO2005084669A1
(en)
*
|
2004-03-01 |
2005-09-15 |
Lek Pharmaceuticals D.D. |
Pharmaceutical composition
|
EP1729766A1
(en)
*
|
2004-03-01 |
2006-12-13 |
LEK Pharmaceuticals D.D. |
Pharmaceutical formulation
|
KR20090029310A
(ko)
*
|
2004-05-05 |
2009-03-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
순도가 높은 칸데사르탄 실렉세틸의 제조
|
CN102512372A
(zh)
*
|
2004-06-08 |
2012-06-27 |
沃泰克斯药物股份有限公司 |
药物组合物
|
IL171137A
(en)
|
2004-09-29 |
2012-01-31 |
Chemagis Ltd |
Use of purified malt donfazil for the preparation of pure pharmaceutical amorphous donfazil hydrochloride
|
US20060160871A1
(en)
*
|
2004-12-07 |
2006-07-20 |
Nektar Therapeutics |
Stable non-crystalline formulation comprising losartan
|
US20090076281A1
(en)
*
|
2005-05-05 |
2009-03-19 |
Medichem, S.A. |
Process for the preparation of losartan and its salts
|
AU2006275413B2
(en)
*
|
2005-08-02 |
2012-07-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
*
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
JP2009513622A
(ja)
*
|
2005-10-27 |
2009-04-02 |
ルピン・リミテッド |
ロサルタンの医薬製剤
|
LT1993360T
(lt)
|
2005-12-28 |
2017-06-12 |
Vertex Pharmaceuticals Incorporated |
N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
|
WO2007098270A2
(en)
|
2006-02-27 |
2007-08-30 |
Vertex Pharmaceuticals Incorporated |
Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
|
BRPI0709567A2
(pt)
|
2006-03-16 |
2011-07-12 |
Vertex Pharma |
inibidores deuterados de protease de hepatite c
|
AP2009004960A0
(en)
*
|
2007-02-27 |
2009-08-31 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
NZ579295A
(en)
*
|
2007-02-27 |
2012-03-30 |
Vertex Pharma |
Inhibitors of serine proteases
|
US8492546B2
(en)
*
|
2007-08-30 |
2013-07-23 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
SI3345625T1
(sl)
|
2008-08-13 |
2021-04-30 |
Vertex Pharmaceuticals Incorporated |
Farmacevtski sestavek in njegove administracije
|
EA020103B1
(ru)
|
2009-01-23 |
2014-08-29 |
Ханми Сайенс Ко., Лтд. |
Твердая фармацевтическая композиция, содержащая амлодипин и лозартан, и способ ее получения
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
AU2011242457A1
(en)
|
2010-04-22 |
2012-11-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
WO2011133951A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
WO2011133953A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US20110288122A1
(en)
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical Compositions and Administrations Thereof
|
MX2013002353A
(es)
|
2010-08-27 |
2013-09-26 |
Vertex Pharma |
Composicion farmaceutica y administraciones de la misma.
|
CA2853299A1
(en)
|
2011-11-02 |
2013-05-10 |
Vertex Pharmaceuticals Incorporated |
Use of (n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) for treating cftr mediated diseases
|
US20130224293A1
(en)
|
2012-02-27 |
2013-08-29 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
WO2013185112A1
(en)
|
2012-06-08 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Pharmaceuticl compositions for the treatment of cftr -mediated disorders
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
CA3028207A1
(en)
|
2012-06-19 |
2013-12-27 |
Intercept Pharmaceuticals, Inc. |
Preparation, uses and solid forms of obeticholic acid
|
AU2014348523B2
(en)
|
2013-11-15 |
2019-01-03 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
|
LT3424534T
(lt)
|
2014-04-15 |
2021-11-10 |
Vertex Pharmaceuticals Incorporated |
Farmacinės kompozicijos, skirtos gydyti ligas, kurių atsiradimui tarpininkauja cistinės fibrozės transmembraninio laidumo reguliatorius
|
MX2017004543A
(es)
|
2014-10-06 |
2017-10-04 |
Vertex Pharma |
Moduladores de regulador de conductancia transmembranal de fibrosis quística.
|
IL277491B
(en)
|
2016-12-09 |
2022-08-01 |
Vertex Pharma |
Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|
US11253509B2
(en)
|
2017-06-08 |
2022-02-22 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
WO2019010092A1
(en)
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
|
US11517564B2
(en)
|
2017-07-17 |
2022-12-06 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
EP3697774A1
(en)
|
2017-10-19 |
2020-08-26 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of cftr modulators
|
WO2019113089A1
(en)
|
2017-12-04 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
CN111757874B
(zh)
|
2017-12-08 |
2024-03-08 |
弗特克斯药品有限公司 |
用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
PT3752510T
(pt)
|
2018-02-15 |
2023-03-15 |
Vertex Pharma |
Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los
|
US20210009560A1
(en)
|
2018-03-30 |
2021-01-14 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of modulators of cftr
|
KR20210089656A
(ko)
|
2018-10-05 |
2021-07-16 |
버텍스 파마슈티칼스 인코포레이티드 |
알파-1 항트립신 조절제
|
PL3880197T3
(pl)
|
2018-11-14 |
2023-07-31 |
Vertex Pharmaceuticals Incorporated |
Sposoby leczenia mukowiscydozy
|
CR20210383A
(es)
|
2018-12-17 |
2021-09-22 |
Vertex Pharma |
Inhibidores de apol 1 y sus métodos de uso
|
UY38630A
(es)
|
2019-04-03 |
2020-10-30 |
Vertex Pharma |
Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
UY38696A
(es)
|
2019-05-14 |
2020-11-30 |
Vertex Pharma |
Moduladores de alfa-1 antitripsina
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
CN114599657A
(zh)
|
2019-08-14 |
2022-06-07 |
弗特克斯药品有限公司 |
Cftr调节剂的结晶形式
|
TW202120517A
(zh)
|
2019-08-14 |
2021-06-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
EP4076670A1
(en)
|
2019-12-20 |
2022-10-26 |
Principia Biopharma Inc. |
Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
WO2022036060A1
(en)
|
2020-08-13 |
2022-02-17 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of cftr modulators
|
US20240002386A1
(en)
|
2020-11-17 |
2024-01-04 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 4-(5-(4-fluorophenyl)-6-(tetrahydro-2h-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
|
JP2023552828A
(ja)
|
2020-12-10 |
2023-12-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
嚢胞性線維症の治療方法
|
JP2024520648A
(ja)
|
2021-06-04 |
2024-05-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ナトリウムチャネルの調節因子としての置換テトラヒドロフラン-2-カルボキサミド
|
CA3221960A1
(en)
|
2021-06-04 |
2022-12-08 |
Vertex Pharmaceuticals Incorporated |
Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
|
WO2022256676A1
(en)
|
2021-06-04 |
2022-12-08 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofuran analogs as modulators of sodium channels
|
AU2022284886A1
(en)
|
2021-06-04 |
2023-11-30 |
Vertex Pharmaceuticals Incorporated |
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
|
EP4347584A1
(en)
|
2021-06-04 |
2024-04-10 |
Vertex Pharmaceuticals Incorporated |
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
|
WO2023150236A1
(en)
|
2022-02-03 |
2023-08-10 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
|
WO2023224924A1
(en)
|
2022-05-16 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of a macrocyclic compounds as cftr modulators and their preparation
|
TW202415662A
(zh)
|
2022-06-14 |
2024-04-16 |
美商普林斯匹亞生物製藥公司 |
2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧雜環丁烷-3-基)哌𠯤-1-基]戊-2-烯腈的固體形式
|
WO2024031081A1
(en)
|
2022-08-04 |
2024-02-08 |
Vertex Pharmaceuticals Incorporated |
Compositions for the treatment of cftr-mediated diseases
|
WO2024054624A1
(en)
|
2022-09-09 |
2024-03-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of alpha-1 antitrypsin
|